Advanced Cardiovascular LLC — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$172,020	4
2024	Research	$6,667	2
2023	Research	$4,000	1
2021	Research	$1,226	2
2020	Research	$18,957	10
2019	Research	$28,103	10

Breakdown

Who paid Research payments · program years 2019–2025

AstraZeneca UK Limited $87,315 1 payment
Amgen Inc. $59,991 1 payment
Regeneron Pharmaceuticals, Inc. $35,959 19 payments
AstraZeneca Pharmaceuticals LP $18,461 1 payment
Bayer HealthCare Pharmaceuticals Inc. $12,920 3 payments
Akcea Therapeutics, Inc. $7,327 2 payments
Sanofi US Services Inc. $5,000 1 payment
Pfizer Inc. $4,000 1 payment

Studies the money was for Research payments · program years 2019–2025

A Phase IIb Two cohort Randomised Placebo controlled Double blind Multicentre Dose ranging Study of AZD5462 in Stable Patients with Chronic Heart Failure $87,315 1 payment
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) $59,991 1 payment
A Phase III Randomised Doubleblind Study to Evaluate the Effect of Balcinrenone Dapagliflozin Compared with Dapagliflozin on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and Impaired Kidney Function $18,461 1 payment
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Praluent on Neurocognitive Function in Patients With Heterozygous Familial Hypercholesterolemia or With Non-Familial Hypercholesterolemia at High and Very High Cardiovascular Risk $14,392 7 payments
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Praluent on Neurocognitive Function in Patients With Heterozygous Familial Hypercholesterolemia Or With Non-Familial Hypercholesterolemia at High and Very High Cardiovascular Risk $13,068 6 payments
BAY 1021189, A Phase 2b open-label clinical study to evaluate the tolerability and safety of an initiation dose of 5 mg of Vericiguat in participants with chronic heart failure with reduced ejection fraction $12,920 3 payments
Long Term Safety Study of PRALUENT in Patients With Heterozygous Familial Hypercholesterolemia or With Non-Familial Hypercholesterolemia at High and Very High Cardiovascular Risk and Previously Enrolled in the Neurocognitive Function Trial $8,499 6 payments
Isis 678354-Cs2 $7,087 1 payment
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients With Type 2 Diabetes POST Worsening Heart Failure $5,000 1 payment
A Lowinterventional Prospective Longitudinal Cohort Study to Collect Digital Functional Assessments and Evaluate Symptoms in Study Participants With Chronic Heart Failure $4,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.